Search research articles
Contact Us
Filters
Showing results (411-420 of 451) with videos related to
Page
of 46
Sort By:
Leukemia
|
January 29, 2013
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
U Platzbecker, F Braulke, A Kündgen, et al.
Palliative Medicine
|
March 23, 2026
A randomized controlled clinical trial of intranasal versus subcutaneous midazolam for agitation in terminal illness (MinTU study)
Hanna Hirschinger, Constanze Rémi, Evelyn Jäger, et al.
Nature Medicine
|
January 25, 2005
Cathepsin L is required for endothelial progenitor cell-induced neovascularization
Carmen Urbich, Christopher Heeschen, Alexandra Aicher, et al.
Leukemia
|
January 9, 2015
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event
M Jawhar, J Schwaab, S Schnittger, et al.
The Journal of Experimental Medicine
|
June 8, 1999
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth
P Schneider, F MacKay, V Steiner, et al.
Annals of Hematology
|
May 25, 2004
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
W K Hofmann, G Heil, C Zander, et al.
Pneumologie (Stuttgart, Germany)
|
January 20, 2011
[Diagnostics and expert opinion of asbestos-induced occupational diseases]
X Baur, M Clasen, A Fisseler-Eckhoff, et al.
Leukemia
|
May 8, 2013
SETBP1 mutation analysis in 944 patients with MDS and AML
F Thol, K J Suchanek, C Koenecke, et al.
Leukemia
|
October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis
M Jawhar, J Schwaab, S Schnittger, et al.
British Journal of Haematology
|
October 8, 2016
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS)
Martin Wermke, Claudia Schuster, Florian Nolte, et al.
Page
of 46
Search research articles
Search
Showing results (411-420 of 451) with videos related to
Sort By:
Page
of 46
Leukemia
|
January 29, 2013
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
U Platzbecker, F Braulke, A Kündgen, et al.
Palliative Medicine
|
March 23, 2026
A randomized controlled clinical trial of intranasal versus subcutaneous midazolam for agitation in terminal illness (MinTU study)
Hanna Hirschinger, Constanze Rémi, Evelyn Jäger, et al.
Nature Medicine
|
January 25, 2005
Cathepsin L is required for endothelial progenitor cell-induced neovascularization
Carmen Urbich, Christopher Heeschen, Alexandra Aicher, et al.
Leukemia
|
January 9, 2015
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event
M Jawhar, J Schwaab, S Schnittger, et al.
The Journal of Experimental Medicine
|
June 8, 1999
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth
P Schneider, F MacKay, V Steiner, et al.
Annals of Hematology
|
May 25, 2004
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
W K Hofmann, G Heil, C Zander, et al.
Pneumologie (Stuttgart, Germany)
|
January 20, 2011
[Diagnostics and expert opinion of asbestos-induced occupational diseases]
X Baur, M Clasen, A Fisseler-Eckhoff, et al.
Leukemia
|
May 8, 2013
SETBP1 mutation analysis in 944 patients with MDS and AML
F Thol, K J Suchanek, C Koenecke, et al.
Leukemia
|
October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis
M Jawhar, J Schwaab, S Schnittger, et al.
British Journal of Haematology
|
October 8, 2016
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS)
Martin Wermke, Claudia Schuster, Florian Nolte, et al.
Page
of 46